Methadone News and Research RSS Feed - Methadone News and Research

Opioid prescribing guidelines that focus high-dose use may need revision, say researchers

Opioid prescribing guidelines that focus high-dose use may need revision, say researchers

Overdoses of opioid pain medications frequently occur in people who aren't chronic users with high prescribed opioid doses--the groups targeted by current opioid prescribing guidelines, reports a study in the August issue of Medical Care. [More]
1 in 4 people with histories of nicotine use, substance abuse likely to use opioid painkillers long-term

1 in 4 people with histories of nicotine use, substance abuse likely to use opioid painkillers long-term

Opioid painkiller addiction and accidental overdoses have become far too common across the United States. To try to identify who is most at risk, Mayo Clinic researchers studied how many patients prescribed an opioid painkiller for the first time progressed to long-term prescriptions. The answer: 1 in 4. People with histories of tobacco use and substance abuse were likeliest to use opioid painkillers long-term. [More]
UC San Diego epidemiologist receives $1.5 million grant for research on HIV, substance abuse

UC San Diego epidemiologist receives $1.5 million grant for research on HIV, substance abuse

Dan Werb, PhD, an internationally noted epidemiologist at University of California, San Diego School of Medicine, has been named one of four inaugural recipients of the Avenir Award, a prestigious $1.5 million research grant from the U.S. National Institute on Drug Abuse, part of the National Institutes of Health (NIH). [More]
Implementation of needle exchange programs can prevent HIV outbreaks in Indiana

Implementation of needle exchange programs can prevent HIV outbreaks in Indiana

Congress needs to immediately lift the ban on federal funding for needle exchange programs to counter the threat of HIV outbreaks among injection drug users like the one that has seen an alarming number of new cases erupt in a single rural Indiana county. [More]
Veterans who died from drug overdoses also prescribed benzodiazepines for pain

Veterans who died from drug overdoses also prescribed benzodiazepines for pain

In a recent study, nearly half of all veterans who died from drug overdoses while prescribed opioids for pain were also receiving benzodiazepines, or benzos, which are common medications for the treatment of anxiety, insomnia and alcohol withdrawal. Veterans prescribed higher doses of benzodiazepines while concurrently receiving opioids were at greater risk of overdose death than those on lower doses of benzodiazepines. [More]
US physicians with waivers increase potential access to effective medication-assisted treatment

US physicians with waivers increase potential access to effective medication-assisted treatment

American physicians with waivers allowing them to provide office-based medication-assisted buprenorphine treatment to patients addicted to opioids were able to increase potential access to effective medication-assisted treatment by 74 percent from 2002 to 2011, according to a new RAND Corporation study. [More]
Braeburn reports positive topline results from Probuphine Phase 3 study for treatment of opioid addiction

Braeburn reports positive topline results from Probuphine Phase 3 study for treatment of opioid addiction

Braeburn Pharmaceuticals, an Apple Tree Partners company, today reported positive topline results from the Phase 3 double-blind, double-dummy clinical study of Probuphine, the investigational subdermal implant containing buprenorphine HCl for the long-term maintenance treatment of opioid addiction. [More]
MedUni Vienna expert suggests pricing strategy to reduce smoking

MedUni Vienna expert suggests pricing strategy to reduce smoking

30% of the estimated 2.3 million smokers in Austria are considered to be heavily tobacco-dependent and, according to experts at MedUni Vienna, require professional treatment. This would mean around 690,000 people. According to Michael Kunze, an expert on smoking at the Center for Public Health at MedUni Vienna, an effective strategy would be to increase the price of tobacco products: "If the price of cigarettes were to rise just one percent above the inflation rate, that would bring about a 0.5% reduction in consumption worldwide." [More]
Total costs of treatment for babies with neonatal abstinence syndrome on the rise

Total costs of treatment for babies with neonatal abstinence syndrome on the rise

As more infants are born to mothers with dependence on prescription pain medications, the costs of treatment for babies with neonatal abstinence syndrome (NAS) have increased dramatically, suggests a report in the March/April issue of the Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine. [More]
Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015. [More]
Study calls for effective strategies to contain potential HDV epidemic in high-risk populations

Study calls for effective strategies to contain potential HDV epidemic in high-risk populations

Researchers from Taiwan determined that individuals with human immunodeficiency virus (HIV) infection or those who inject illicit drugs have a higher risk of becoming infected with the hepatitis D virus (HDV) in that country. [More]

Heroin-assisted treatments benefit some drug users

Drug users who do not benefit from conventional treatments for heroin addiction should be able to access the drug through the health system, urges a Canadian expert in The BMJ today. [More]
MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

Nektar Therapeutics reported that partner AstraZeneca announced today that MOVANTIK (naloxegol) has launched in the United States. On September 16, 2014, the US Food and Drug Administration (FDA) approved MOVANTIK as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain. [More]
Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol) in the US, in line with the Daiichi Sankyo strategy to expand its US portfolio through strategic alliances, in addition to internal R&D and acquisitions. [More]
Opioid withdrawal in Ontario newborns increases 15-fold

Opioid withdrawal in Ontario newborns increases 15-fold

The number of newborns suffering from opioid withdrawal increased 15-fold in Ontario over 20 years, according to research published today in CMAJ Open. [More]
Use of methadone drug to treat pain increases mortality risk

Use of methadone drug to treat pain increases mortality risk

Outside the hospital, use of methadone to treat pain carries a 46 percent increased risk of death when compared to the equally effective but more costly alternative, morphine SR (sustained release). [More]
New experimental study shows immunotherapy can reduce acute effects of heroin

New experimental study shows immunotherapy can reduce acute effects of heroin

Immunotherapy could have a place in the treatment of substance abuse in the future. A specific antibody can reduce the acute effects of heroin, according to a new experimental study at the Norwegian Institute of Public Health. [More]
European countries implement ATOME project to study improved access to essential painkillers

European countries implement ATOME project to study improved access to essential painkillers

Governments in 12 European countries are to implement the recommendations of research into why more patients are not receiving essential painkillers. [More]
Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients. [More]
Montefiore Medical Center receives $3.5M grant to advance treatment for hepatitis C

Montefiore Medical Center receives $3.5M grant to advance treatment for hepatitis C

Montefiore Medical Center received a $3.5 million grant as part of the $10 million Health Care Innovation Award from the Center for Medicare & Medicaid Services to identify, diagnose and treat people with hepatitis C (HCV). [More]
Advertisement
Advertisement